Cloud-native drug discovery is accelerating in the U.S. and Canada, powered by AI-driven workflows and scalable cloud infrastructure. Spending is projected to grow from ~$1.5B in 2025 to ~$6.9B by 2030 as pharma and biotech firms enhance AI use in synthesis, trials, and compliance. AI adoption will rise from 30% to 65%, cutting drug development time to ~12 months, reducing R&D costs by 50%, and improving compliance by 75%. Compound success rates will grow from 8% to 22%, improving clinical outcomes. By 2030, cloud-native architectures will make drug discovery faster, cheaper, and more compliant, transforming global healthcare innovation.